Document is current
Any future updates will be listed below
-
Authors
Gardner, Joshua https://orcid.org/0000-0002-4520-108X
Abrams, Simon Timothy
Toh, Cheng-Hock
Parker, Alan L. https://orcid.org/0000-0002-9302-1761
Lovatt, Charlotte https://orcid.org/0000-0002-2606-8930
Nicolson, Phillip L. R. https://orcid.org/0000-0002-4843-2975
Watson, Steve P.
Grice, Sophie
Hering, Luisa
Pirmohamed, Munir
Naisbitt, Dean J.
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (NIHR135073, NIHR135073, NIHR135073)
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 28 May 2024
First Online: 5 June 2024
Competing interests
: M.P. has received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co‐funded by MRC and Roche, UCB, Eli Lilly and Novartis). He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. M.P. and D.J.N. are part of the IMI Consortium ARDAT (). All other authors declare no competing interests.
